Aging and gerontology researchers
You study cognition, brain aging or health outcomes in older adults.
Aging, AgeTech & Digital Aging Care
Statistics and study design for aging research, for evaluating home, long-term and dementia care programs, and for AgeTech pilots of sensors, wearables and digital tools.
Who this is for
Teams we help in this field.
Health-system and care-program evaluators
You need to show whether a home-care or long-term-care program works.
AgeTech start-ups
You are running a pilot and need evidence that a funder or buyer will take seriously.
Audiences we welcome, not a list of clients.
Questions we help answer
What teams in this field ask us.
- Did our care program change outcomes, and how sure can we be?
- How do we evaluate a program when we cannot randomize?
- How do we handle drop-out and deaths in an older cohort?
- How do we measure adoption and continued use?
- How do we turn raw sensor or wearable data into reliable measures?
- How many sites or participants does our evaluation need?
What you receive
- An evaluation design: with the comparison, outcomes and timeline agreed first.
- A sample-size justification: that a funder or ethics board can follow.
- An adherence and outcome analysis: who used the tool, how much, and what changed.
- A report written for decision makers: plain findings, figures and the limits of the evidence.
- Reproducible code: for every number in the report.
Methods we use
The methods specialists ask about.
- Mixed-effects models
- Survival and competing-risk analysis
- Propensity scores
- Interrupted time series
- Adherence metrics
- Time-series features
- Multiple imputation
- Brain-aging measures
Evidence
Published work behind this area.
White matter injury, brain aging, and cognitive decline beyond amyloid/tau
Looked beyond amyloid and tau at white-matter injury, brain aging and cognitive decline.
Read the paper (external site)Differences in brain aging between sexes in Parkinson's disease
Found differences in brain aging between women and men with Parkinson's disease.
Read the paper (external site)Neuroanatomical Signature of the Transition from Normal Cognition to MCI in Parkinson's Disease
Described the brain changes that mark the move from normal cognition to MCI.
Read the paper (external site)Boundaries
We analyze research, program and pilot data. We do not provide care, assess individual people, or build, sell or endorse products. A monitoring tool with a medical purpose may be a regulated device; that stays with the developer. Personal health information stays with your organization.
Packages that fit
Start at the right scale.
The same packages and prices on every page. Each starts with a written scope.
Research Diagnostic
Fixed priceCAD 495
- 60-minute video call
- Two-page risks and next-steps memo
- Optional 30-minute debrief
Paid in full at booking.
Memo within 5 business days of the call.
Ask about thisAnalysis Plan Sprint
Fixed priceCAD 1,250
- Analysis and validation plan
- Scoped sample-size or power calculation
- Methods text or reviewer response
50% to start; 50% on delivery.
Delivery date agreed in the written scope.
Ask about thisData-to-Results Sprint
FromCAD 3,000
- Agreed analysis and quality-control log
- Figures, tables and methods text
- R or Python code and recorded environment
50% to start; 50% on delivery.
Final price and delivery date agreed after scoping.
Ask about thisRelated
Go deeper.
Questions
About working in aging, agetech & digital aging care.
Can you evaluate a program that has already started?
Often, yes, if outcomes were recorded before and after it began. We tell you honestly what the data can and cannot show.
Can you design our pilot before it starts?
Yes, and that is the best time. A short plan written before the pilot saves most of the problems we see afterwards.
Will you recommend or endorse our product?
No. We report what the evaluation shows. Independence is what makes the report useful to you.
Do you work with administrative or care-record data?
Yes, when it is de-identified and your organization has approved its use for the evaluation. Your organization remains the data custodian.
Do you handle drop-out and deaths properly?
Yes. In older cohorts they are expected. We choose methods such as multiple imputation or competing-risk models and explain the choice.
What does it cost?
Most evaluations start with a Research Diagnostic (CAD 495) or an Analysis Plan Sprint (CAD 1,250). Larger analyses are quoted after scoping.
Discuss a aging, agetech project.
Start with a short, non-confidential description. We reply with a suggested next step.